A medical case report describes a 75-year-old patient who had received a kidney transplant. After getting a COVID-19 infection, this patient developed a rare and serious blood condition called complement-mediated thrombotic microangiopathy, or CM-TMA. Doctors treated the patient with a medication called ravulizumab, and the patient's condition improved.
The report did not mention any specific safety problems or side effects from the treatment in this one patient. The main reason to be careful with this information is that it comes from just one person's experience. A single case cannot tell us how well a treatment works for most people or what the risks might be.
This case reminds doctors to consider CM-TMA as a possible diagnosis in transplant patients who get sick, and that age alone should not rule it out. For readers, the realistic takeaway is that this is an early, interesting observation from one patient. It is not evidence that this treatment is proven safe or effective for others. More research in many more patients is needed to understand if ravulizumab is a reliable option for transplant patients with this rare condition.